View as markdown
Concepts › Signals › Profile › Identifiers & reference

description

Business description of the company.

Watch this signal live on real tickers: Open in Explore →

At a glance

Typetext
GroupProfile
CategoryIdentifiers & reference
Update cadencepost-close daily
Universeall tickers
Historynone — live row only, not historized (no as-of reads)
Nullableyes — NULL where not applicable

Which company this is: name, IDs (CIK, FIGI), listing status, contact, branding, employees.

Query it

Every applicable form factor, grouped by endpoint family. Swap YOUR_KEY for the value from /dashboard/keys. Response payloads are real captures, sampled 2026-08-18 and trimmed — your run's values and dates will differ.

Use scan /v2/scan

The whole market through a WHERE clause — this signal composed freely with any other column. Docs →

Live — the whole market, ranked by this column
curl -G "https://api.tickerbot.io/v2/scan" \
  --data-urlencode "q=description IS NOT NULL" \
  -d "order=description" -d "columns=description" \
  -H "Authorization: Bearer YOUR_KEY"
Response (sampled 2026-08-18, trimmed)
{
 "as_of": "2026-08-18T00:23:26.235Z",
 "query": {
  "q": "description IS NOT NULL",
  "limit": 2,
  "order": "description",
  "dir": "desc",
  "fields": [
   "description"
  ],
  "full": false,
  "universe": null,
  "asset_class": null
 },
 "count": 2,
 "results": [
  {
   "ticker": "VTVT",
   "name": "vTv Therapeutics Inc. Class A Common Stock",
   "asset_class": "stocks",
   "asset_type": "CS",
   "price": 31.195,
   "day_change_pct": 0.0357,
   "gap_pct": -0.0063,
   "relative_volume": 0.3966,
   "market_cap": 119092311,
   "description": "vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small-molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin (TTP399), a novel, small-molecule, liver-selective glucokinase activator (GKA) currently being evaluated as a potential oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). In addition, the company is also engaged in the research and development of other candidates in its pipeline through collaborations with academic partners and license agreements, which include TTP273, HPP737, TTP-RA, Mavodelpar (HPP593), HPP971, and HPP3033, being studied and developed to counter various chronic diseases."
  },
  {
   "ticker": "QURE",
   "name": "uniQure N.V.",
   "asset_class": "stocks",
   "asset_type": "CS",
   "price": 47.94,
   "day_change_pct": -0.014,
   "gap_pct": -0.0111,
   "relative_volume": 0.6739,
   "market_cap": 3372594951,
   "description": "uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs."
  }
 ]
}

Same grammar on scan and webhooks. This column is live-tense only — it isn't historized, so ?asof= reads and series pulls don't carry it.

Related signals — Identifiers & reference